Literature DB >> 6790625

A novel human T cell antigen preferentially expressed on mature T cells and shared by both well and poorly differentiated B cell leukemias and lymphomas.

M Kamoun, M E Kadin, P J Martin, J Nettleton, J A Hansen.   

Abstract

A new lymphocyte differentiation antigen shared by all normal T cells and some malignant B cells was defined by a monoclonal antibody designated 12.1. This antibody reacted with all peripheral blood T cells but not with normal B cells and B cell lines. Analysis with a fluorescence activated cell sorter showed that the expression of 12.1 antigen changes during T cell maturation. Most thymocytes, blasts of acute T cell leukemia, and cells from established leukemic T cell lines bear a small amount of 12.1 antigen. In contrast the majority of peripheral blood T cells, activated T cells, and leukemic T cells of the Sezary syndrome bear a large amount of 12.1 antigen. Unexpectedly, antibody 12.1 reacted with leukemic cells from most patients with B-type chronic lymphocytic leukemia (CLL) and some patients with lymphosarcoma cell leukemia (LSCL). Among these leukemias, expression of the 12.1 antigen was not correlated with the stage of B cell maturation, with the amount of surface immunoglobulin on the cells, or with the presence or absence of monoclonal gammapathy. In a comparative serologic analysis the antigen defined by antibody 12.1 was distinct from the p67 T cell antigen (defined by monoclonal antibody 10.2) that is also known to be expressed by B-type CLL cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6790625

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  Blocked ricin-conjugated T cell immunotoxins: effect of anti-CD6-blocked ricin on normal T cell function.

Authors:  R A Rasmussen; S L Counts; J M Lambert; A R Collinson
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 2.  New targets of therapy in T-cell lymphomas.

Authors:  Jack Erter; Lapo Alinari; Kamruz Darabi; Metin Gurcan; Ramiro Garzon; Guido Marcucci; Mark A Bechtel; Henry Wong; Pierluigi Porcu
Journal:  Curr Drug Targets       Date:  2010-04       Impact factor: 3.465

3.  Molecular linkage of the mouse CD5 and CD6 genes.

Authors:  O Lecomte; J B Bock; B W Birren; D Vollrath; J R Parnes
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

Review 4.  T-cell clones and T-cell receptors.

Authors:  F W Fitch
Journal:  Microbiol Rev       Date:  1986-03

5.  Phenotype of chronic lymphocytic leukemia (CLL) B-cells. B-CLL cells express the Leu-8 antigen.

Authors:  A Cafaro; M Napolitano; V Zoli; L Pacilli; I Mezzaroma; A De Laurenzi; F Pandolfi
Journal:  Blut       Date:  1987-01

6.  MRC OX-52: a rat T-cell antigen.

Authors:  A P Robinson; M Puklavec; D W Mason
Journal:  Immunology       Date:  1986-04       Impact factor: 7.397

7.  Surface glycoproteins as markers of the cellular status of B chronic lymphocytic leukaemia lymphocytes.

Authors:  V A Brown; S K Smith; A E Dewar; G Stockdill; A H Maddy
Journal:  Clin Exp Immunol       Date:  1985-10       Impact factor: 4.330

8.  Molecular cloning and expression of T11 cDNAs reveal a receptor-like structure on human T lymphocytes.

Authors:  P H Sayre; H C Chang; R E Hussey; N R Brown; N E Richardson; G Spagnoli; L K Clayton; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

9.  Five antigens on human T cells detected by mouse monoclonal antibodies.

Authors:  I Tsuge; R Ueda; K Nishida; R Namikawa; M Seto; T Maruyama; S Takamoto; H Matsuoka; S Torii; K Ota
Journal:  Clin Exp Immunol       Date:  1984-11       Impact factor: 4.330

10.  Reactivity of Leu 1 and T101 monoclonal antibodies with B cell lymphomas (correlations with other immunological markers).

Authors:  T Al Saati; G Laurent; P Caveriviere; F Rigal; G Delsol
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.